C-KIT IS EXPRESSED IN SOFT TISSUE SARCOMA OF NEUROECTODERMIC ORIGIN AND ITS LIGAND PREVENTS APOPTOSIS OF NEOPLASTIC CELLS by RICOTTI, E. et al.
c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin
and Its Ligand Prevents Apoptosis of Neoplastic Cells
By Emanuela Ricotti, Franca Fagioli, Emanuela Garelli, Claudia Linari, Nicoletta Crescenzio,
Alberto L. Horenstein, Paola Pistamiglio, Sergio Vai, Massimo Berger, Luca Cordero di Montezemolo,
Enrico Madon, and Giuseppe Basso
During development, mice with mutations of stem cell factor
(SCF) or its receptor c-kit exhibit defects in melanogenesis,
as well as hematopoiesis and gonadogenesis. Consequently,
accumulating evidence suggests that the c-kit/SCF system
plays a crucial role in all of these processes and in tumors
which derive from them. Especially in neuroblastoma (infant
tumors of neuroectoderm crest derivation such as melano-
cytes) it would appear that an autocrine loop exists between
c-kit and SCF, and that the functional block of the c-kit
receptors with monoclonal antibodies (MoAbs) results in a
significant decrease in cellular proliferation. We studied the
expression and role of c-kit and SCF in cell lines of soft tissue
sarcoma of neuroectodermic origin, such as Ewing’s sar-
coma (ES) and peripheral neuro-ectodermal tumors (PNET).
Using flow cytometry with MoAb CD117 PE, c-kit expression
was highlighted in all six of the cell lines examined. This
receptor was specifically and functionally activated by SCF,
as shown by the binding experiments and the intracellular
phosphotyrosine and immunoprecipitation studies that were
performed. Using reverse transcriptase polymerase chain
reaction analysis, five of the six cellular lines expressed the
mRNA of SCF. In the medium measured by using an enzyme-
linked immunosorbent assay, low concentrations of SCF
were found: only the TC32 cellular line produced significantly
higher levels (32 pg) than control. In serum-free culture the
addition of SCF reduced the percentage of apoptotic cells
from 25% to 90% in five out of the six cellular lines. This
observation was confirmed by (1) the functional block of
c-kit with MoAb: after 7 days of culture more than 30% of the
cells were apoptotic (range 31.5% to 100%) in five out of six
cell lines and there was also a decrease in the percentage of
cells in phase S, and (2) c-kit antisense oligonucleotides: in
the cellular lines treated with oligonucleotides (in relation to
the untreated lines) there was a notable reduction (P F .001)
both in the absolute number of cells and the 3H-thymidine
uptake. These results indicate that ES and PNET express
c-kit and its ligand SCF and that SCF is capable of protecting
the tumor cells against apoptosis. Furthermore, the reverse
transcriptase–polymerase chain reaction performed on the
biopsies revealed the presence of mRNA both of SCF and
c-kit in practically all of the samples studied. Our in vitro data
lead us to assume that SCF may also inhibit tumor cell
apoptosis in vivo.
r 1998 by The American Society of Hematology.
THE c-kit PROTO-ONCOGENE, encoding a 145- to 165-kDmembrane-bound glycoprotein of the transmembrane
tyrosine kinase family, has been identified as a homologue of
the sarcoma retrovirus HZ4-FeSV transforming gene.1 The
ligand for c-kit is alternatively known as the stem cell factor
(SCF), mast cell growth factor, steel factor, or kit ligand.2,3
During development, mice with the c-kit or SCF mutations
exhibit defects in melanogenesis, as well as hematopoiesis and
gonadogenesis.4 Consequently, accumulating evidence suggests
that the c-kit/SCF system plays a crucial role in all of these
processes.5-9
This system is also present on the neoplastic counterpart of
these cells.10,11 In particular, the mRNA coexpression of the
SCF and c-kit has been reported in certain cases of acute
myeloid leukemia,12 round cell pulmonary tumors,13 and breast
carcinoma.14 This has led to the hypothesis of the existence of
an autocrine loop between SCF/c-kit.
Cohen et al15 suggested the presence of this loop in neuroblas-
toma, neuroectoderm derived infant tumors, and also showed
that the c-kit block with the use of a monoclonal antibody
(MoAb) is capable of inducing a reduction of the growth of
colonies in agar and of the percentage of cells in S phase.15
Comparable experiments, conducted on human neuroblastoma
lines, with the anti–c-kit blocking antibody, have shown that the
SCF could inhibit the apoptosis rather than directly stimulate
proliferation.16
No data is available in relation to the c-kit/SCF role in soft
tissue sarcoma of neuroectodermic origin, such as Ewing’s
sarcoma (ES) and peripheral neuroectodermal tumor (PNET).17
In this report we investigated whether c-kit and SCF are
expressed in ES and PNET and whether c-kit and SCF play a
role in growth regulation of these malignancies.
MATERIALS AND METHODS
Cell lines and tissue samples. Six cellular lines were studied: three
deriving from ES—6647, TC106, and PDE02; and three from PNET—
TC32, PDN12, and PDN13. The 6647, TC106, and TC32 was kindly
provided by Dr Pagani (Department of Biomedical Science and Human
Oncology, University of Turin).18 The PDE-02, PDN12, and PDN13
were obtained in our laboratory from biopsies at diagnosis.19
The human megakaryoblastic leukemia cell line M-07e20 and an
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell line were
used as controls. All cell lines were maintained in RPMI 1640 media
supplemented with 10% fetal calf serum (FCS) and 0.2 mg/mL of
penicillin/streptomycin. Thirteen surgical biopsies collected from five
ES and eight PNET were obtained from our pathology laboratory after
rigorous histological evaluation. In three cases cytogenetic results were
not available. The classical cytogenetic translocation t(11;22)(q24;q21)
was identified in 9 out of the 10 remaining cases, and in the last case, a
PNET, the i(1q), t(2;21)(p21;q22) was shown.
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Cytofluorimetric detection of surface c-kit receptor. With the anti-
CD117 phycoerythrin (PE)-conjugated MoAb (Ancell Corp, Bayport,
MN), 5 3 105 cells were incubated at 4°C for 30 minutes, then washed
twice in phosphate-buffered saline (PBS) and analyzed by flow
cytometry (Epics-XL; Coulter, Miami, FL). PE-conjugated isotypic
antibody was used as control and M-07e was used as a positive control.
To quantify the average number of c-kit receptors per cell, the
Quantum (TM) 27 R-Phycoerythrin-conjugated kit (Flow Cytometry
Standard Corporation, San Juan, Puerto Rico) was used. This contains a
set of calibrated standards, with four populations of microbeads
displaying increasing and predetermined fluorescence intensity (ex-
pressed in terms of the number of molecules of equivalent soluble
fluorochromes [MESF]) and one reference blank population. Using this
method, the relative channel number obtained by flow cytometry
analysis of a cell population is directly transformed into the number of
MESF. The linear regression equation, correlating the channel number
with the specific MESF value, was calculated using specific software
(Quickcal V2.0; Flow Cytometry Standard Corporation).
Fig 1. Dose-response curve in apoptosis inhibition obtained by
using exogenous SCF (0, 0.01, 0.05, 0.1, 0.5, and 1.0 mg/106 cells). The
dose of 0.5 mg/106 cells has been considered appropriate.
Fig 2. c-kit Expression on human sarcoma cell lines analyzed by flow cytometry. Control MoAb (ª) and anti CD117-PE (—). (A) M07e, (B) 6647
(ES), (C) TC32 (PNET), (D) TC106 (ES), (E) PDN13 (PNET), (F) PDN12 (PNET), (G) PDE02 (ES).
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SCF binding. To block process receptor internalization, 1 3 105
cells were collected by culture and treated with PBS at 4°C with 0.01%
NaN3. Cells were then incubated for 60 minutes at 4°C with 10 µL of
biotinylated SCF (rh Stem Cell Factor Biotin Conjugate; R&D Systems,
Minneapolis, MN) at a concentration of 0.6 µg/mL or with a biotinyl-
ated negative control. Ten microliters of avidin-fluorescein isothiocya-
nate (FITC) were added and incubated for a further 30 minutes at 4°C in
the dark. The cells were then washed to remove unreacted avidin
fluorescein and resuspended in 0.2 mL of PBS for final flow cytometric
analysis. An anti-SCF neutralizing antibody (R&D Systems) was used
as a control to show binding specificity.
Staining of intracellular phosphotyrosine. One hundred microliters
of cells suspended at 1 3 106/mL in PBS containing 1% FCS were
mixed with an equal volume of PBS containing 2% paraformaldehyde
(PFA), 1 mmol/L EDTA, 2 mmol/L NaVO4, and 0.1% saponin. After 10
minutes of incubation at room temperature, the cells were washed twice
in PBS and stained with antiphosphotyrosine-PE MoAb (Py-PE kindly
provided by F. Lund-Johansen, DNAX Research Institute, Palo Alto,
CA).21 Immunostained cells were washed in PBS and resuspended in
0.5% PFA and kept at 4°C until cytofluorimetric analysis.
Immunoprecipitation studies. Cells were resuspended in serum-free
RPMI medium, incubated for 24 hours at 37°C 5% CO2, then untreated
and SCF treated cells (10 minutes with 0.5 µg/106 cells) were rapidly
pelleted and resuspended in lysis buffer (10 mmol/L TrisHCl, pH 8.6;
1.5 mmol/L MgCl2; 0.14 mol/L NaCl; 1% NP40; 2 mmol/L phenylmeth-
ylsulfonylfluoride; 2 µg/mL leupeptin; 2 µg/mL aprotinin; 1 mg/mL
pepsin A). Lysates were incubated for a minimum of 30 minutes on ice,
frozen, thawed, and centrifuged at 13,000 rpm at 4°C for 20 minutes.
Immunoprecipitation of c-kit was performed on the clarified supernatant
with a mouse monoclonal anti-human c-kit neutralizing antibody (anti
rh SCFR; Boehringer, Mannheim, Germany) coupled to sepharose-
proteinA (SIGMA Chemical Co, St Louis, MO).
After rotating for 16 hours at 4°C, immunoprecipitates were washed
twice with lysis buffer, once with lysis buffer without NP-40, and once
with Tris HCl 50 mmol/L, pH 6.5. Samples then underwent elution from
proteinA with sodium dodecyl sulfate (SDS) sample buffer. The
resulting protein was subjected to 7% SDS-polyacrylamide gel electro-
phoresis (PAGE). Protein was transferred electrophoretically to polyvi-
nylidenedifluoride (PDVF). The filter was incubated with a 3% albumin
bovine (SIGMA) blocking solution in TBS-Tween (20 mmol/L Tris
HCl, pH 7.6; 137 mmol/L NaCl; 0.1% Tween 20) overnight at 4°C.
Antiserum anti-phosphotyrosine PY20 (Transduction Laboratories, Lex-
ington, KY) was added to the same solution and incubation was carried
out for 2 hours at room temperature. The filters were then washed three
times (10 minutes each) with TBS-Tween and reacted for 1 hour at room
temperature with rabbit anti-mouse horseradish peroxidase-conjugated
(Transduction Laboratories). The filter was washed as above and
visualized using ECL western blotting analysis system (Amersham,
Buckinghamshire, UK).22
The PDVF filter was stripped of antibody by 200 mmol/L glycine, pH
2.2; SDS 0.1%; and Tween-20 1%, for 2 hours, then reprobed with
MoAb anti c-kit (Boehringer).
Reverse transcriptase-polymerase chain reaction (RT-PCR). The
RT-PCR was performed according to the previously reported method.16
The total RNA was extracted by means of the guanidine salts and
phenol-chloroform method using Ultraspec RNA (Biotecx Laboratories
Inc, Houston, TX). The cDNA products of all samples and a lymphoblas-
toid cell line, used as a negative control, were obtained by using 2 µg of
total RNA and a poliT primer (Reverse Transcription System, PCR-
related; Promega, Madison, WI). To verify the quality of the RNA of
each sample, RT-PCR amplification of b-actin was performed with
appropriate primers (Clontech Lab, Palo Alto, CA) and a single band of
the expected size was obtained (data not shown). The same cDNA is
used for RT-PCR amplification for SCF and c-kit. The PCR primers for
SCF amplification were upstream primer 58ATTCAAGAGC-
CCAGAACCCA38 and downstream primer 58CTGTTACCAGCCAAT-
GTACG38. For c-kit amplification the primers were upstream primer
58GAGTTGGCCCTAGAGTTAGA38 and downstream primer 58CCTG-
GAGTTGGATGCAAGTT38. The specific primers for the PCR reaction
were synthesized with an Oligonucleotide Synthesizer 381A (Applied
Biosystems, Foster City, CA). The cycling condition for amplification
was as follows: denaturation at 96°C for 3 minutes, then 35 cycles of
94°C for 1 minute, 64°C for 45 seconds, and 72°C for 1 minute; a
thermal cycler (Perkin Elmer-Cetus, Norwalk, CT) was used. The PCR
Fig 3. Cytofluorimetric profile of
SCF specific binding and SCF binding
inhibition after coincubation with 20
mg of goat anti-human SCF neutraliz-
ing antibody in a representative case
(6647, ES) of sarcoma cells. The heavy
solid line represents the background of
the negative staining control, the light
solid line represents the SCF-FITC stain-
ing, and the dotted line represents the
SCF-FITC staining after coincubation
with anti-human SCF antibody.
Table 1. c-kit Expression on Human Sarcoma Cell Lines
Cell Line MESF
M-07e 365,960
PDN12 124,021
TC32 129,877
PDN13 81,960
6647 330,815
PDE02 98,374
TC106 63,935
c-kit Expression on human Sarcoma cell lines (megakaryoblastic—
M-07e; PNET—PDN12, PDN13, and TC32; ES—6647, PDE02, and
TC106) obtained by flow cytometry analysis and transformed in terms
of number of MESF.
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products were separated on 2% agarose gel containing 1 µg/mL
ethidium bromide.
Detection of soluble SCF by tumor cell lines. Chemically defined
media of cell lines were collected after 72 hours of culture and the SCF
protein concentration in the cell supernatants was quantified by using an
enzyme-linked immunosorbent assay (R&D Systems) with a sensibility
of 4 pg/mL. The medium was used as the control.
Exogenous SCF. To evaluate the potential role of the SCF, experi-
ments were performed in serum-free conditions. Cells were cultured in
RPMI 1640 supplemented with monotioglycerol (SIGMA), 7.5 1025;
Albumine Bovine (SIGMA), 2%; and 0.2 mg/mL of penicillin/
streptomycin and Insulin Transferrine Sodium Selenite media supple-
ment (SIGMA) diluted to 1:100, following the manufacturer’s instruc-
tions.
Cells were incubated with 0.5 µg/106 cells of human recombinant
SCF (Stem Cell Technologies, Vancouver) and evaluated at 24 hours for
apoptosis. Selection of the appropriate working concentration of the
SCF was based on a dose-response curve in which the cells were
incubated with 0, 0.01, 0.05, 0.1, 0.5, and 1.0 µg/106 cells of exogenous
SCF and evaluated at 24 hours for apoptosis (Fig 1).
Evaluation of apoptosis. The cells, cultured in serum-free condi-
tions, were fixed by adding formaldehyde (1% in PBS) for 15 minutes
on ice. After resuspension in PBS, cells were stored at 4°C in ethanol
(70% in PBS). To perform apoptosis analysis, cells were rehydrated in
PBS and cytocentrifuged. The slides were fixed by immersion for 5
minutes in a solution of ethanol:acetic acid (2:1) and then washed twice
in PBS and incubated with a cacodylate buffer (0.2 mol/L potassium
cacodylate; 2.5 mmol/L Tris HCl; 2.5 mmol/L/cobalt chloride; and 0.25
mg/mL bovine serum albumin, pH 6.6) containing 5 U of TdT
(Boehringer) and 0.5 µmol/L of Bio-dUTP (Boehringer) for 1 hour at
37°C. Slides were rinsed in PBS and incubated with 5 µg/mL of
fluoresceinated streptavidin (Boehringer) at room temperature for 30
minutes in the dark. Slides were rinsed in PBS, 0.4 µg/mL of propidium
iodide was added for 1 minute, and slides were mounted with glycerol
for microscopic analysis.23 More than 300 cells were double tested.
Effect of anti-c-kit neutralizing antibody on sarcoma cell growth.
The MoAb anti-human c-kit neutralizing antibody (anti-rhSCFR; Boeh-
ringer) at a final concentration of 0.4 µg/104 cells was added to the cells
Fig 4. Cytofluorimetric detection of intracellu-
lar phosphotyrosine in PDN12 (PNET) cell line. The
dotted line (ª) represents phosphotyrosine in
cells in serum-free condition for 24 hours. The
solid line (—) shows the phosphotyrosine 10 min-
utes after stimulation with rhSCF (0.5 mg/106
cells).
Fig 5. (A) SCF-induced tyrosine phosphorylation of c-kit. TC32
(PNET) and M-07e (control) cells were incubated for 10 minutes with
0.5 mg/106 cells rhSCF, lysed, and immunoprecipitated with c-kit
antiserum. Proteins were resolved by 7% SDS-PAGE, transferred to
PDVF, and immunoblotted with antiphosphotyrosine antibody. Mo-
lecular mass of protein standards are indicated in kD. (TC32 2 SCF),
TC32 untreated cells; (TC32 1 SCF), TC32 SCF treated cells; (M-07e 2
SCF), M-07e untreated cells; (M-07e 1 SCF), M-07e treated cells. (B)
c-kit Immunoblot. The immunoblot from (A) was stripped and re-
probed with an anti–c-kit MoAb.
Fig 6. SCF mRNA RT-PCR analysis. The specific 409- and 494-bp
PCR fragments are visible in 5 out of 6 (83%) of sarcoma cell lines.
Lane 1, 6647 (ES); lane 2, TC32 (PNET); lane 3, TC106 (ES); lane 4,
PDN13 (PNET); lane 5, PDN12 (PNET); lane 6, PDE02 (ES); lane 7, B
lymphoblastoid EBV-transformed cell line SCF mRNA neg; lane 8, No
DNA.
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growing in the complete medium. The antibody was added every 72
hours and the cells were assayed at 24 to 72 hours and 7 days for S phase
and apoptosis. The experiments were repeated using an isotypic MoAb
(mouse anti-human Vb-8, kindly provided by F. Malavasi, Department
of Genetics Biology and Biochemistry, University of Turin) as a
negative control. Selection of the appropriate working concentration
was based on dilution experiments on the M-07e cell line (data not
shown).
Propidium iodide staining. Cultured in serum-free conditions, 5 3
105 cells were centrifuged and the pellets treated with automated DNA
staining kit (DNA-prep; Coulter). Tubes were placed at 4°C in the dark
overnight. The PI fluorescence of individual nuclei was measured by
flow cytometry and the results obtained analyzed by Multicycle specific
software (Phoenix Flow Systems, San Diego, CA).
Treatment of cells with antisense oligonucleotide. Two cell lines,
the ES (6647) and the PNET (TC32) were selected for antisense
experiments. The experiments were performed by adopting the specific
SCF receptor antisense oligonucleotide kit (Biognostik Antisense kit;
Biognostik GmbH, Go¨ttingen, Germany) according to the manufactur-
er’s instructions. The cells were washed four times and resuspended at
2.5 3 104 cells/mL in cell culture media. Aliquots of 100 µL/well were
placed in 96-well plates and allowed to adhere for at least 1 hour.
Specific c-kit oligo antisense and a control were added directly in the
respective wells, in order to make a 2 µmol/L solution. The cells were
maintained at 37°C in 5% CO2 and checked daily to examine the
different morphology between antisense treated and control cells. The
oligos were added daily (2 µL/well). After 7 days, 3 wells were counted
in a Neubauer’s chamber, the others received 4 µCi/mL of 3H-thymidine
(Amersham), incubation was continued for 6 hours, and cells were then
harvested on glass fiber filter paper. Filter strips were dried and the
incorporated radioactivity was measured in a scintillation counter
(Canberra Packard International S.A., Zurich, Switzerland). All assays
were performed in triplicate.
RESULTS
Direct immunofluorescence analyses. In all of the six cell
lines the surface expression of c-kit was tested in base line
culture conditions. All cell lines were positive for c-kit expres-
sion, though with a different expression (Fig 2) minimum of
63935 MESF in the TC106 (ES) cell line and a maximum of
330815 MESF in the 6647 (ES) cell line (Table 1). The positive
control M07e cell line showed 365960 MESF.
SCF binding. The c-kit binding ability was analyzed by
using biotinylated rh-SCF. The cytofluorimetric detection of the
SCF-FITC bound to cells was positive in 6 out of 6 (100%)
samples tested with specific inhibition. A representative case is
shown (6647 ES) in Fig 3.
Protein tyrosine phosphorylation induced by rhSCF. Using
flow cytometry, we tested the ability of the SCF to induce
protein tyrosine phosphorylation in the six cell lines. We observed a
10-fold increase, compared with untreated cells, of intracellular
phosphotyrosine 10 minutes after stimulation with rhSCF (a represen-
tative case PDN12 is shown in Fig 4). The specific c-kit phosphory-
lation after SCF treatment was shown by using Western blotting
analysis on c-kit immunoprecipitates (Fig 5).
Fig 7. SCF and c-kit mRNA RT-PCR analysis in 13 sarcoma’s biopsies (lanes 1 through 13), and B lymphoblastoid EBV-transformed cell line SCF
and c-kit mRNA neg (lane 14). (A) The specific c-kit 749-bp PCR fragment is visible in 12 out of 13 (92%) samples. (B) The SCF specific 409- and
494-bp PCR fragments are visible in 13 out of 13 (100%) samples.
Fig 8. SCF activity on apoptosis inhibition in sarcoma cell lines.
The evaluation was performed in serum-free conditions 24 hours
after administration of exogenous SCF (0.5 mg/106 cells). Each experi-
ment was performed at least twice (mean of two reproducible
experiments). Five of six (83%) of the cell lines showed an evident
reduction in percentage of the apoptotic cells. (0), SCF2; (G), SCF1.
Table 2. Soluble SCF Production by Sarcoma Cell Lines
Cell Line SCF Production (pg/mL)
PDN12 12.0
TC32 36.0
PDN13 8.5
6647 5.5
PDE02 9.0
TC106 5.0
Medium alone 5.0
Soluble SCF production by Sarcoma cell lines (PNET—PDN12,
PDN13, and TC32; ES—6647, PDE02, and TC106) grown in serum-free
medium assessed using enzyme immunoassay.
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SCF and c-kit RNA expression. All of the cellular lines
studied, apart from TC106 (ES), expressed the mRNA of SCF
(Fig 6). In addition, 13 sarcoma biopsies were examined for
c-kit and SCF mRNA expression; 12 out of the 13 (92%)
samples examined seemed to coexpress RNA for SCF and c-kit;
whereas one sample only showed SCF mRNA (Fig 7A and B).
Detection of SCF production by tumor cell lines. Detect-
able levels, higher than medium alone, were found in five of six
supernatants. The TC106 (ES) cell line showed no SCF
production compared with medium alone. Four cell lines
showed a low production level (less than 12 pg), whereas TC32
(PNET) production was 36 pg (Table 2).
Effect of the SCF on apoptosis. After 24 hours, five out of
the six cell lines (without SCF) showed apoptosis ranging from
15.5% in PDE02 (ES) to 83% in TC106 (ES). This phenomenon
was not present in TC32 (PNET). SCF addition, in the
responders’ cell lines, showed a decrease in the percentage of
apoptotic cells in relation to nontreated cells, with a more
evident decrease in 6647 (ES) (90%) and in PDE02 (ES) (54%)
(Fig 8).
S Phase and apoptosis after exposure to anti–c-kit neutraliz-
ing MoAb. To test whether c-kit expression contributes to
Sarcoma cell proliferation or apoptosis, the cell lines were
treated in culture with neutralizing c-kit MoAb. After culture
with anti–c-kit neutralizing antibody, cell cycle analysis in three
cell lines (6647 [ES], TC32 [PNET], and TC106 [ES]) showed
an increase of the S phase after 24 hours and a decrease at 72
hours, with a maximum effect after 7 days (Fig 9). In the last 2
PNET cell lines (PDN12 and PDN13) the addition of neutraliz-
ing anti–c-kit antibody had a decreasing effect of S phase at 24
hours, reaching 0 value in the PDN13 after 7 days of culture.
All cell lines showed increased apoptotic phenomenon. In
fact, on day 7, five out of six (83%) had more than 30%
apoptotic cells (range, 31.5% to 100%). By contrast, the control
cells treated with Vb-8 antibody at the same dilution did not
modify the apoptosis of S phase. The PDE02 (ES) cell line
showed only 16% of apoptosis after 7 days (Fig 10), but a
Fig 9. S phase and apoptosis
in sarcoma cell lines treated with
anti c-kit neutralizing antibody
0.4 mg/104 cells for 24 hours, 72
hours, and 7 days. The cells were
grown in complete medium. Con-
trol cells were treated with Vb-8
antibody, and the value at 7 days
was reported (the results at 24
hours and 72 hours were compa-
rable). Each experiment was per-
formed in duplicate (mean of two
reproducible experiments).
Fig 10. Specific action of c-kit neutralizing antibody in two lines.
PDE02 (ES) (A,C,E,G) and 6647 (ES) (B,D,F,H) cultured in complete
medium. Cytofluorimetric profile of the propidium iodide staining of
DNA content in basal condition (A,B) with 0.4 mg/104 cells of Vb-8 for
7 days (C,D), with 0.4 mg/104 cells of anti–c-kit neutralizing antibody
for 72 hours (E,F) and for 7 days (G,H). The reduction of S phase and
the increment of the apoptotic phenomenon appear at 72 hours (E,F)
and is more evident after 7 days (G,H) (13% in PDE02 and 46% in
6647). These results were confirmed by TdT assay.
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longer incubation time (14 days) increased apoptotic percentage
(50%) (data not shown).
Effect of c-kit antisense oligonucleotides on growth of cell
lines. To study the specific role of the SCF receptor, we
examined the effect of c-kit sense and antisense oligonucleo-
tides on the growth of two sarcoma cell lines. The treatment of
6647 (PNET) and TC32 (ES) cell lines with c-kit antisense
oligonucleotides resulted in an inhibition of cell growth.
Treated cells showed a growth depression in comparison with
untreated cells or sense-oligos–treated cells. This observation
was directly shown by the significant (P , .001) reduction in
the absolute number of cells. Even the 3H-thymidine uptake
data showed a significant (P , .001) reduction of growth
activity in the oligo-treated cells (Fig 11A and B).
DISCUSSION
This is the first study that underlines the presence of the
c-kit/SCF system in ES and PNET and indicates that SCF is
involved in cellular proliferation and, above all, is protecting
cells from apoptosis. c-kit Was found in all of the cell lines
Fig 11. Cell growth inhibition
by c-kit antisense oligonucleo-
tides. Untreated and treated 6647
cells (sense or antisense oligos 2
mmol/L) incubated 7 days at 37°C
5% CO2. (A) Absolute number of
cells, mean of three different ex-
periments. (`), mean; (h), SD;
(') SEM. (B) 6647 oligos-treated
cells were incubated in triplicate
for 6 hours with 4 mCi/mL of
3H-thymidine. (`), mean; (h), SD;
('), SEM. The differences be-
tween treated and untreated
cells showed a statistical signifi-
cance (P F .001).
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examined, with a consistent level of positivity that was compa-
rable, in certain cases, with that of the M-07e line which was
used as a positive control. The binding experiments and the
intracellular phosphotyrosine and immunoprecipitation studies
showed how this receptor is both specifically and functionally
activated by the exogenus SCF. Furthermore, five out of the six
cell lines expressed the mRNA of the SCF. Correspondingly, the
analysis of the mRNA of c-kit and SCF performed on bioptic
samples confirmed and reinforced these observations, suggest-
ing that the hypothesis of a c-kit/SCF autocrine loop.
Significant levels of SCF in the medium were only found in
one cellular line (TC32). This may indicate that there was either
a failed translation of the message or immediate consumption,
by means of interaction with the receptor. The experiments with
c-kit blocking antibody and antisense oligonucleotides could
suggest that the second hypothesis is more likely. On the other
hand, the receptor’s activation in TC32 cell line after exposure
to exogenous SCF could indicate that endogenus SCF is not
able to activate all receptors.
Moreover, the addition of exogenous SCF in the serum-free
culture, the c-kit receptor block, and the antisense oligonucleo-
tide experiments (performed only on two cellular lines: 6647
[ES] and TC32 [PNET]), clearly indicated that the SCF is
capable of both increasing cellular proliferation and, more
importantly, inhibiting the apoptosis in the ES and PNET.
This fact is hardly surprising for a variety of reasons. SCF
plays a crucial role in the hematopoiesis, development, and
organization of the neural crest and the cells that derive from the
crest (eg, melanocytes).4 In the hematopoiesis, in synergy with
other growth factors, it stimulates the proliferation of the more
immature staminal cells and the commissioned progenitors,
protecting them from apoptosis.7,8,24-26 In certain acute myeloid
leukemias, the SCF, either by itself or together with other
growth factors, is capable of stimulating the self-maintenance
and proliferation of leukemia blasts.12 In some human mela-
noma lines that present mRNA for both SCF and c-kit, the SCF
can increase the percentage of S phase cells and the formation
of colonies in agar.27 Similar results were obtained in neuroblas-
toma, infant tumors of neuroectoderm derivation, producing the
functional block of the c-kit receptors with an MoAb. In this
manner Cohen et al15 were the first to assume the function of the
autocrine loop between the SCF and its receptor, but a more
recent study further indicated that the main role of the SCF in
neuroblastomas could be that of protecting the cells from
apoptosis.16
Our study underlines the presence of this growth factor and
its receptors in ES and PNET, and also explains a functional
apoptosis-preventing role. Even if the data indicate that preven-
tion of apoptosis is not complete and decreases if the experi-
ments lasted for 3 days (data not shown), it however suggests
that other factors are necessary for the complete cell survival.
Whether c-kit and SCF play a significant role in the growth of
these soft tissue sarcoma of neuroectodermic origin remains to
be determined. The hypothesis that the SCF and c-kit mRNA
transcripts from tumor samples were not derived from tumor
cells themselves, but from contaminating hematopoietic cells
within the sample is not probable fact. All the biopsies were
obtained from massively infiltrated tissue. Furthermore, in two
cases in which suitable samples were available the c-kit
expression was shown by flow cytometry (data not shown). The
results obtained on the cellular lines would indicate that
SCF/c-kit plays a functional role. Therefore, it can be strongly
suggested that this role is also present in tumors in vivo. This
data also suggests that among the growth factors used in
therapeutic protocol, SCF must be used cautiously with these
patients.
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